News | May 25, 2018

First-in-human Electroporation Ablation Study Finds Pulsed Electric Fields Can Target Specific Tissue For Atrial Fibrillation

Pulsed electric field (PEF) energy ablates non-thermally by creating microscopic pores in cell membranes

First-in-human Electroporation Ablation Study Finds Pulsed Electric Fields Can Target Specific Tissue For Atrial Fibrillation. #HRS2018 #HRS18

May 25, 2018 — Data from the first-in-human study using pulsed electric field (PEF) energy ablate heart tissue in the treatment atrial fibrillation shows very positive evidence and may usher in a new era of tissue-specific, ultra-rapid ablation. This was according to researchers presenting this late-breaking study at Heart Rhythm 2018, the Heart Rhythm Society’s 39th Annual Scientific Sessions.

Standard thermal energy sources rely on time-dependent conductive heating/cooling, and ablates all tissue types indiscriminately. PEF energy ablates non-thermally by creating microscopic pores in cell membranes, called electroporation. PEF is highly tissue selective since characteristic threshold field strengths induce necrosis in specific tissues and leave other surrounding tissue unharmed. 

This is attractive to consider for AF ablation since cardiomyocytes have among the lowest threshold values (400 V/cm) of any tissue, which allows tissue selectivity and minimizing ablation of non-target tissue (including the esophagus, phrenic nerve, etc.). PEF also is fast (energy delivered over just a few seconds), and the absence of coagulative necrosis obviates the risk of pulmonary vein (PV) stenosis. 

PEF ablation was performed in two trials using custom systems. The Iowa Approach Inc. system (Figure 1) uses a epicardial linear catheter for PV plus left atrium (LA) encircling to generate a posterior box lesion during concomitant cardiac surgery. The other system used an endocardial over-the-wire catheter for percutaneous transeptal PV isolation. For all cases, endocardial LA-PV voltage maps were created pre- and post-encirclement (using either the Boston Scientific Rhythmia or Biosense Webster Carto electromapping systems).

At two centers, 22 patients were ablated under general anesthesia: A) 7 epicardial patients during valve (6) or CABG (1) surgery - 69±6.4 years, 2F/5M, 6 PAF/1 PerAF, and B) 15 endocardial patients —64±4.6 yrs, 8F/7M, all PAF. Box lesions were successful in 6 out of 7 epicardial patients (86%) using two lesions per patient. The failure was related to equipment malfunction. Including mapping, procedure time for epicardial ablation was 55±21 min. 

Catheter PVI was successful in all 57 PVs in 15 patients (100%) using 3.3±0.5 lesions/PV. Procedure time was 67±10 min, catheter time (PEF catheter entry to exit of LA) = 19±2.5 min (range 16 - 23), total PEF energy delivery time < 60 sec/pt, fluoroscopy time = 12±4.0 min. There were no complications.

The researchers said these data may help usher in a new era of tissue-specific, ultra-rapid ablation of atrial fibrillation. They said PEF appears promising for AF ablation, but additional studies are warranted.

Electroporation is discussed as a new technique in the VIDEO Current State of Atrial Fibrillation Ablation Technologies

Find links to all the Heart Rhythm 2018 late-breaking studies.


Related Content

News

Oct. 24, 2024 — Medtronic plc has announced United States Food and Drug Administration (FDA) approval of the Affera ...

Home October 30, 2024
Home
News

Oct. 18, 2024 — Boston Scientific Corp. recently announced it has received U.S. Food and Drug Administration (FDA) ...

Home October 21, 2024
Home
News

May 15, 2024 —CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for cardiac ...

Home May 15, 2024
Home
News

May 13, 2024 — Innovative Health, Inc. announced that recent growth in single-use device reprocessing has delivered ...

Home May 13, 2024
Home
News

October 10, 2023 — Axon Therapies, a private company focused on addressing a root cause of heart failure, announced 6 ...

Home October 10, 2023
Home
News

August 9, 2023 — Boston Scientific Corporation announced it has received U.S. Food and Drug Administration (FDA) ...

Home August 09, 2023
Home
News

January 31, 2023 —Imricor, a global leader in real-time interventional cardiac magnetic resonance (iCMR) ablation ...

Home January 31, 2023
Home
News

December 21, 2022 — Stereotaxis, a global leader in robotic technologies for the treatment of cardiac arrhythmias ...

Home December 21, 2022
Home
News

October 24, 2022 — Acutus Medical, Inc, an arrhythmia management company focused on improving the way cardiac ...

Home October 24, 2022
Home
News

May 13, 2022 — Acutus Medical, an arrhythmia management company focused on improving the way cardiac arrhythmias are ...

Home May 13, 2022
Home
Subscribe Now